[go: up one dir, main page]

WO2001028578A3 - A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME - Google Patents

A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME Download PDF

Info

Publication number
WO2001028578A3
WO2001028578A3 PCT/US2000/029278 US0029278W WO0128578A3 WO 2001028578 A3 WO2001028578 A3 WO 2001028578A3 US 0029278 W US0029278 W US 0029278W WO 0128578 A3 WO0128578 A3 WO 0128578A3
Authority
WO
WIPO (PCT)
Prior art keywords
pglu
glu
pro
retina
injuries
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/029278
Other languages
French (fr)
Other versions
WO2001028578A2 (en
Inventor
James L Meyerhoff
Michael L Koenig
Joseph B Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter Reed Army Institute of Research
Original Assignee
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter Reed Army Institute of Research filed Critical Walter Reed Army Institute of Research
Priority to AU15747/01A priority Critical patent/AU1574701A/en
Publication of WO2001028578A2 publication Critical patent/WO2001028578A2/en
Publication of WO2001028578A3 publication Critical patent/WO2001028578A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A neuroprotectant composition wherein the active ingredient is pGLU-GLU-PRO-NH2 or a combination of pGLU-GLU-PRO-NH2(EEP) and N-tert-Butyl-α-(2-sulfophenyl)nitrone(SPBN) or other nitrone. A method of treating and preventing diseases and injuries of the brain, spinal cord and retina is also presented by administering the endogenous tripeptide EEP to a subject as a neuroprotectant or by administering EEP in combination with SPBN or other nitrone.
PCT/US2000/029278 1999-10-22 2000-10-20 A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME Ceased WO2001028578A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15747/01A AU1574701A (en) 1999-10-22 2000-10-20 A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16097299P 1999-10-22 1999-10-22
US60/160,972 1999-10-22

Publications (2)

Publication Number Publication Date
WO2001028578A2 WO2001028578A2 (en) 2001-04-26
WO2001028578A3 true WO2001028578A3 (en) 2001-11-22

Family

ID=22579259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029278 Ceased WO2001028578A2 (en) 1999-10-22 2000-10-20 A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME

Country Status (2)

Country Link
AU (1) AU1574701A (en)
WO (1) WO2001028578A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122524B2 (en) 2001-02-05 2006-10-17 Neurotell Ag Tripeptides and tripeptide derivatives for the treatment of postlesional disease of the nervous system
US7129213B2 (en) 2001-02-05 2006-10-31 Neurotell Ag Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
US7163922B2 (en) 2001-02-05 2007-01-16 Neurotell Ag Tripeptide derivatives for the treatment of postlesional diseases of the nervous system

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289404B2 (en) 2011-02-04 2016-03-22 Hough Ear Institute Methods for treating brain injury
US20220362325A1 (en) * 2019-09-26 2022-11-17 S.I.S Shulov Innovative Science Ltd. Compositions and methods for treating degenerative, age-related and trauma-induced disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4906614A (en) * 1985-01-23 1990-03-06 Gruenenthal Gmbh Method of treating posttraumatic nervous injuries with dipeptide derivatives
US5508305A (en) * 1993-12-23 1996-04-16 Oklahoma Medical Research Foundation 2, 4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceuticals
WO2000064440A1 (en) * 1999-04-22 2000-11-02 Department Of The Army, U.S. Government Treatment of and/or prophylaxis against brain and spinal cord injury

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4906614A (en) * 1985-01-23 1990-03-06 Gruenenthal Gmbh Method of treating posttraumatic nervous injuries with dipeptide derivatives
US5508305A (en) * 1993-12-23 1996-04-16 Oklahoma Medical Research Foundation 2, 4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceuticals
WO2000064440A1 (en) * 1999-04-22 2000-11-02 Department Of The Army, U.S. Government Treatment of and/or prophylaxis against brain and spinal cord injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOENIG M L ET AL: "Neuroprotection by the TRH-like peptide pGLU-GLU-PRO-NH2 (EEP).", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, 28th Annual Meeting of the Society for Neuroscience, Part 1;Los Angeles, California, USA; November 7-12, 1998, pages 459, XP000993252, ISSN: 0190-5295 *
PEKARY A EUGENE ET AL: "Electroconvulsive seizures increase levels of pGlu-Glu-Pro-NH2 (EEP) in rat brain.", PEPTIDES (NEW YORK), vol. 20, no. 1, 1999, pages 107 - 119, XP000993222, ISSN: 0196-9781 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122524B2 (en) 2001-02-05 2006-10-17 Neurotell Ag Tripeptides and tripeptide derivatives for the treatment of postlesional disease of the nervous system
US7129213B2 (en) 2001-02-05 2006-10-31 Neurotell Ag Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
US7163922B2 (en) 2001-02-05 2007-01-16 Neurotell Ag Tripeptide derivatives for the treatment of postlesional diseases of the nervous system

Also Published As

Publication number Publication date
WO2001028578A2 (en) 2001-04-26
AU1574701A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
MY131810A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
CA2446435A1 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
EP1234586A3 (en) Hepatoselective pharmaceutical actives
AU684059B2 (en) Application of riluzole in the treatment of Parkinson's disease and Parkinsonian syndromes
EP0489108A4 (en) Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
PT88985A (en) Process for the preparation of nasal and ophthalmic pharmaceutical compositions containing azelastine
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
AU645023B2 (en) Compositions and method for treating painful, inflammatory or allergic disorders
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
CA2123049A1 (en) Pharmaceutical containing the p40 subunit of interleukin 12
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
CA2284774A1 (en) Theobromine antitussive compositions
NZ506408A (en) Pharmaceutical compositions
WO1994017792A3 (en) Compositions and methods for transdermal drug delivery
WO2002051379A3 (en) Thixotropic nasal spray
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
EP1090635A3 (en) Use of ferulic acid for treating hypertension
EP1023901A4 (en) Ameliorant for hepatitis c remedial effect and application thereof
EP0373771A3 (en) New pharmaceutical uses for cystatins
WO2001085188A3 (en) Use of echinacea as a hematinic agent
EP1108429A3 (en) An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP